

REMARKS

The Office action dated July 5, 2006, has been received and carefully reviewed.

The method and composition of the invention have been limited to the peptide analogue of formula I (SEQ ID No. 2).

The objection to claim 92 has been obviated by appropriate amendment.

The rejection of claims 79 and 92 under 35 USC 112, second paragraph, has been obviated by appropriate amendment. Accordingly, favorable reconsideration of the rejection is urged.

It is believed that the presently amended claims are clearly patentable of the Hirai et al. (US 4,659,696) and Mehlem (US 2003/0162721) references.

Accordingly, Applicants urge the Examiner to favorably reconsider the pending rejections under 35 USC 102(b) and 35 USC 103(a), in the light of the amended claims.

It is believed by the Applicants that the present application is now in condition for allowance and early notice of such action is earnestly solicited. If any final points remain that can be clarified by telephone, Examiner Desai is respectfully encouraged to contact Applicants' attorney at the number indicated below.

Applicants hereby petition the Commissioner for Patents

to extend the time for reply to the final Office Action dated July 5, 2006, for two (2) months from October 6, 2006, to December 5, 2006. A duly completed credit card authorization form is attached to effect payment of the extension fee.

Respectfully submitted

Malcolm J. MacDonald

Date: December 4, 2006

Malcolm J. MacDonald
Reg. No. 40,250
Tel: (703) 837-9600 Ex. 24